India Piperacillin/Tazobactam Market to Grow at a Substantial Rate During the Forecast Period | TechSci Research
SummaryAccording to TechSci Research report, the India piperacillin/tazobactam market is expected to grow at a substantial rate during the forecast period on account of its suitability for the treatment of urinary tract infections.
- Author Company: TechSci Research Pvt Ltd
- Author Name: Shipra Joshi
- Author Email: email@example.com
- Author Website: https://www.techsciresearch.com
Growing prevalence of bacterial infections is expected to drive the growth of India Piperacillin/Tazobactam market during the forecast period.
According to TechSci Research report, “India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, the India piperacillin/tazobactam market is expected to grow at a substantial rate during the forecast period on account of its suitability for the treatment of urinary tract infections. Piperacillin and tazobactam injections are used for the treatment of appendicitis in adults and pediatric patients, which in turn is expected to drive the market growth during the forecast period.
Additionally, uncomplicated as well as complicated skin and skin structure infections, such as cellulitis, ischemic/diabetic foot infections, etc. are known to be well treated by this API drug which is projected to boost the growth of India piperacillin/tazobactam Market. Also, side effects observed due to consumption of piperacillin/tazobactam include headache, trouble sleeping, rash, nausea, constipation, and diarrhea, among others, which can act as impediment to the market growth over the coming years. Additionally, piperacillin/tazobactam is suitable to treat intra-abdominal infections which is further estimated to accelerate the market growth during the forecast period.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "India Piperacillin/Tazobactam Market"
The India piperacillin/tazobactam market is segmented based on route of administration, distribution channel, source, application, end user, company, and region. In terms of application, the market is fragmented into intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, community acquired pneumonia and others. Out of which, the nosocomial pneumonia is expected to dominate the market in the next 5 years which can be attributed to effectiveness of this drug in treating nosocomial pneumonia.
Based on route of administration, the market can be segmented into intramuscular and intravenous. The intravenous route of administration is expected to dominate the market in the coming years on account of certain advantages it offers such rapid response, and easily control over the dosage of the drug. Furthermore, intravenous route of administration is much useful in situations of poor gastrointestinal absorption, which is further forecast to contribute to the growth of the segment.
Aristo Pharmaceuticals Ltd, Radicura Pharmaceuticals Pvt. Ltd., Tauras Laboratories Pvt. Ltd., Taj Pharmaceuticals Ltd., Corona Remedies Pvt. Ltd., Bestochem Formulations (India) Pvt. Ltd., Alpa Laboratories Ltd., Medical Pharma Ltd., Cipla Ltd., Lupin Laboratories Ltd and others are some of the leading players operating in India piperacillin/tazobactam market. Companies operating in the market are using organic strategies such as product launches, mergers and acquisitions, research collaborations to boost their share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7296
Customers can also request for 10% free customization on this report.
“India piperacillin/tazobactam market is expected to witness substantial growth during the forecast period on account of the rising initiatives by the government of the country for API manufacturing and drug development. Additionally, piperacillin/tazobactam API is used in intensive care medicine (pneumonia, peritonitis) which is further expected to fuel the market growth through FY2027. Growing prevalence of skin and tissue infections amongst population is forecast to bolster to demand for piperacillin/tazobactam in the market over the next 5 years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal Infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, has evaluated the future growth potential of India piperacillin/tazobactam market and provides statistics & information on market size, structure and future market growth.
The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India piperacillin/tazobactam market.
Browse Related Reports:
Global Hydroxychloroquine and Chloroquine Market By Type (Injectables & Tablets), By Route of Administration (Oral v/s Intravenous), By Strength (100mg, 250mg & 500mg), By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others), By Region, Competition, Forecast & Opportunities, 2030
Global Immunosuppressants API Market By Method (Synthetic Chemistry, Peptide Chemistry, Fermentation, Chromatographic Purification), By Application (Autoimmune Disease, Organ Transplant), By Type (Corticosteroids, Janus Kinase Inhibitor, Calcineurin Inhibitors, mTOR Inhibitor, Others), By Product (Tablets, Capsules, Liquids, Injections), By APIs (Tacrolimus, Sirolimus, Everolimus, Mycophenolate Mofetil, Mycophenolate Sodium), By End User (Biotechnology & Biopharmaceutical Companies, CMOs, CROs, CDMOs, Others), By Region, Competition, Forecast & Opportunities, 2025
Mr. Ken Mathews
708 Third Avenue,
New York – 10017
For more market research blogs visit: https://techsciblog.com/